Back to search

BIA-Brukerstyrt innovasjonsarena

Gut microbiota profile recognition in IBD patients

Alternative title: Identifisering av tarm mikrobiota profiler i IBD pasienter

Awarded: NOK 16.0 mill.

Project Manager:

Project Number:

326538

Project Period:

2021 - 2024

Funding received from:

Location:

Partner countries:

Genetic Analysis’ (GA) mission is visualizing the human microbiota health by easily accessible and reliable bacteria profiling tools. GA has developed and launched the GA-map® platform, a standardized method for gut microbiota testing. The patented GA-map® technology utilizes a pre-determined targets (PDT) approach, where a standardized set of bacteria targets are built into the assay, and this bacteria panel remains unchanged during the lifetime of the product. This approach meets the requirements for clinical routine use. As of today, there are no solutions able to predict if an individual inflammatory bowel disease (IBD) patient will suffer from mild or severe disease course and finding the appropriate treatment scheme is therefore still an unmet medical need. The intestinal microbiota represents a dynamic environment in which the relative balance of the composition of pro- and anti-inflammatory bacteria species is known to be highly relevant. Mapping of the intestinal microbiota can therefore provide a unique insight to the mechanisms predicting disease course to find the most effective treatment regime. In this project, GA will develop an easy to use, in vitro diagnostic test for profile recognition in IBD patients. Through gut bacteria profile recognition, the test will provide actionable results to allow for informed decisions regarding disease management and treatment.

Genetic Analysis’ (GA) mission is visualizing the human microbiota health by easily accessible and reliable bacteria profiling tools. GA has developed and launched the GA-map® platform, a standardized method for gut microbiota testing. The patented GA-map® technology utilizes a pre-determined targets (PDT) approach, where a standardized set of bacteria targets are built into the assay, and this bacteria panel remains unchanged during the lifetime of the product. This approach meets the requirements for clinical routine use. As of today, there are no solutions able to predict if an individual IBD patient will suffer from mild or severe disease course and finding the appropriate treatment scheme is therefore still an unmet medical need. The intestinal microbiota represents a dynamic environment in which the relative balance of the composition of pro- and anti-inflammatory bacteria species is known to be highly relevant. Mapping of the intestinal microbiota can therefore provide a unique insight to the mechanisms predicting a disease course, and to find the most effective treatment scheme. In this project, GA will develop an easy to use, in vitro diagnostic test for profile recognition in IBD patients. Through gut bacteria profile recognition, the test will provide actionable results to allow for informed decisions regarding disease management and treatment. Importantly, the intervention can be used by any molecular diagnostics laboratory, and will therefore be easily accessed by the health care. The development and validation of the test will be done in collaboration with university hospitals and R&D partners at the forefront in this research field internationally. The successful completion of this project will provide a non-invasive tool for profile recognition useful in guidance to identify the best treatment option for the individual IBD patient.

Activity:

BIA-Brukerstyrt innovasjonsarena